explore

For the second time in as many years, Google’s health tech spinout Verily is pivoting. The company announced Tuesday that it will phase out its chronic disease management app Onduo over the next year and a half as it transitions to a new, “evolved” product called Lightpath.

Lightpath Metabolic, expected to be available in 2026, will not only include programs for people with type 1 and type 2 diabetes and hypertension — as the current iteration of Onduo does — but will also offer GLP-1 drug prescriptions. It will also use artificial intelligence and data from devices such as continuous glucose monitoring (CGM) devices to personalize the care, said Myoung Cha, Verily’s chief product officer.

advertisement

But becoming just one of many apps that uses AI assistants or offers GLP-1 telehealth prescriptions is a surprisingly unoriginal choice for a venture that began its life with a goal to “defeat Mother Nature.” Verily started with “moonshot” ideas like wristbands that would detect cancer and abandoned projects like a contact-lens continuous glucose monitor while searching for a direction over the last nine years amid turnover among employees and executives.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

Totals $468 per year

Starter

$30

for 3 months, then $39/month

Then $39/month

Annual

$399

Save 15%

Save 15%

11+ Users

Custom

Savings start at 25%!

Savings start at 25%!

2-10 Users

$300

Annually per user

$300 Annually per user

Get unlimited access to award-winning journalism and exclusive events.